Science Bulletin, 31 March, 2025, DOI：https://doi.org/10.1016/j.scib.2025.03.055

Efficacy and safety of an mRNA encoding neutralizing antibody against SARS-CoV-2 in non-human primates

Hang Chi, Suo-Qun Zhao, Yun-Peng Liu, Xiao-Chuan Xiong, Xia Zhong, Xing-Xing Suo, Xing-Yao Huang, Can Yue, Jing-Jing Zhang, Zhe Cong, Na Li, Fei-Xue Du, Ting Chen, Jian-Rong Ma, Lei Wang, Bo Ying, Yong-Qiang Deng, Ji-Ye Yin, Xiangxi Wang, Jing Xue, Cheng-Feng Qin

Abstract

The tremendous success of mRNA vaccine during the COVID-19 pandemic has captured attention globally and highlighted the transformative potential of mRNA technology in addressing infectious diseases. In comparison to conventional protein antibody-based therapies, the delivery of mRNA-encoding antibodies presents a cost-effective and versatile approach with several advantages. These include eliminating the laborious process of in vitro protein expression, enabling flexible manufacturing processes, and eliciting rapid therapeutic responses. However, the clinical application of mRNA-encoded antibodies for infectious diseases remains limited to date, only one such construct—mRNA-1944—has been assessed in non-human primates and approved for phase I clinical trial. Several challenges hampered the broader clinical application of mRNA-encoded antibody therapies, including the requirement for higher dosages for intravenous administration, limited pharmacodynamic and pharmacokinetics data, as well as the lack of safety and efficacy profiles in non-human primates.

Article link：https://www.sciencedirect.com/science/article/pii/S209592732500338X?via%3Dihub